Shanghai MicroPort Endovascular MedTech Group Co 688016.SS · CNY
Health Care · Shanghai · 🇨🇳 China
86.72
-1.21%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai MicroPort Endovascular MedTech Group Co
Its shares trade on Shanghai under the ticker 688016.SS. It has been listed since 22 July 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.35bn and net income of CN¥563.2m. At that date it held total assets of CN¥4.64bn and shareholders' equity of CN¥3.98bn.
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, production, and sale of aortic and peripheral vascular interventional medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2019-07-22. The firm's main products include the aortic stent graft system for aortic minimally invasive interventional procedures, the intraoperative stent system for open surgery, as well as the peripheral vascular stent system and peripheral balloon dilatation catheters for the treatment of peripheral vascular diseases. The firm mainly distributes its products to the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 22 Jul 2019
- Employees
- 786
- Website
- endovastec.com ↗
Leadership
Pay as last reported
- Mr. Jonathan ChenChairman of the Board, since 2023
- Ms. Chunfang LiFinance DirectorCN¥182,000
- Mr. Ke ChenSenior Director- Supply ChainCN¥1.7m
- Mr. Hao LiuSenior Director - Treatment Program Promotion
- Mr. Qing ZhuGeneral Manager, Director, since 2018CN¥3.6m
- Mr. Genyong QiuDeputy General Manager, Secretary of the Board
- Mr. Zhenyu YuanDeputy General Manager, General Manager of BluevastecCN¥2.2m
- Mr. Qingfu HuoDirector
- Ms. Shasha MengDirector
- Mr. Daxiao ShiIndependent Director
- Mr. Chengli SongIndependent Director
- Mr. Xiaojie YeIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai MicroPort Endovascular MedTech Group employs 786 skilled employees in Shanghai.
- The company's aortic stent graft system is a key product for minimally invasive procedures.
- MicroPort's peripheral vascular stent system serves domestic market needs effectively.
Weaknesses
- The firm's main distribution is limited to the domestic market in China.
- Shanghai MicroPort's products are primarily focused on vascular interventional devices.
- The company's IPO date was July 22, 2019, which is a fixed point.
Opportunities
- Expanding into international markets could leverage MicroPort's vascular device expertise.
- The growing demand for vascular treatments in China presents a significant opportunity.
- MicroPort can develop new products for peripheral vascular disease treatment.
Threats
- Competition from other medical device companies in China is increasing.
- The domestic market's reliance on MicroPort's products may face regulatory changes.
- Shanghai's location could pose logistical challenges for global expansion.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.